What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Canvert-M is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. At the onset of a migraine attack, an adequate amount of Canvert-M roll-on should be applied to the areas of the forehead, temporal, behind the ears, and the base of the neck. If the patient's headache persists after 30 minutes, a second dose can be used.”In the company’s words, NCT07093138 on ClinicalTrials.gov
- Tested for
- Migraine Disorders
- Main trialPhase 4
- “Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks. The primary objective was to assess the reduction in headache intensity using a 4-point scale (0=no headache, 1=mild…”In the company’s words, NCT07093138 on ClinicalTrials.gov
Other drugs for Migraine Disorders
- ElismetrepTriGemX Bio, Inc. · Tanabe Pharma Corporation · Phase 3
- UbrogepantAbbVie · Phase 3
- EptinezumabH. Lundbeck A/S · Phase 3
- BR005-036CBrise Pharmaceuticals Co., Ltd. · Phase 3
- AtogepantAbbVie · Phase 3
- ErenumabAmgen · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 16 Sep 2025 | Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026